It took nearly six months (and 16,000 hot glue gun sticks) for Arizona schoolkids to recreate the massive Army machine, which ...

Now they’re being clogged with AI slop. Scientific publishing has always had its plumbing problems. Even before ChatGPT, journal editors struggled to control the quantity and quality of submitted work ...

According to researchers, McPherson’s experience is a microcosm of the perils of ed tech. Fifty years after Apple began ...

While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, Recursion announced positive Phase 1b/2 results for REC-4881, which is its ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Space and time aren’t just woven into the background fabric of the universe. To theoretical computer scientists, time and space (also known as memory) are the two fundamental resources of computation.

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...